Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
“iT Bra could be link to early breast cancer detection
10tv.com
PUBLISHED: 05/12/16 10:06 AM EDTUPDATED: 05/19/16 06:21 PM EDT
Columbus, Ohio
Ohio State University is testing what could someday become "magic 8-ball" for diagnosing breast cancer.
It's called the iTBra.
Doctors at the OSU James Cancer Hospital and Solove Research institute call it hope.
"The concept behind it is basically that when cancer forms in the breast, it changes the circadian rhythm in the breast," explains Dr. William Farrar, the principal Investigator behind a new clinical study now underway at OSU.
When a tumor builds its own blood supply, it increases heat. Circadian rhythm is the differentiation in temperature over a period of time.
The "bra" is more in actuality, a medical device that sticks to the breast with metal sensors embedded that can detect the rise in temperature. Dr. Farrar says this technology is particularly important to women who have dense breast tissue.
"The whole idea about when to do mammograms, how often you get them; this may help identify what group of patients need to get a mammogram earlier and in the dense population, which ones need to get an MRI or some other testing to detect cancers," he adds.
Cyrcadia Health, based in Reno, Nevada, is the company developing this wearable technology now in clinical trial at Ohio State. According to its website, the iTBra demonstrated an 87% correlation to a verified, clinical diagnosis of breast cancer including with those patients with dense breast tissue.
Dr. Farrar, who started the initial study of the iTBra in 1988, says this new phase of testing will focus on women who have had mammograms and have been told by their doctors to return for a biopsy.
"It's the same principle," says Dr. Farrar.
"Increased heat production, we can find it easier. The computer and technology behind it has improved tremendously."
Dr. Farrar stresses that by no means does this new technology mean women should replace getting mammograms. He says he considers this as just another tool in the toolbox for doctors in the fight against cancer. However, Dr. Farrar says the exciting aspect of this study is that someday, women might one day be able to buy this "smart" bra at any drug store and get results similar to a pregnancy test.
If you would like more information about this study, call the James at 1-800-293-5066.
Register or donate: Susan G. Komen Race for the Cure in Columbus
Something must be going on. Contacted Ohio State Uni cancer clinic last fall which I also posted in one of my previous post and yes they were still enrolling for the iT Bra clinical trial.
Sorry for the miss spelled words in my previous post , so much for voice recognition???
You’re right, should be getting much better PPS exposure as iT Bra debuts in Asia.
Just yesterday I am American doctor recently diagnosed with breast cancer had a mammogram
That was beg., and 12 months later she’s got advanced breast cancer.
He actually stated, that maybe she should have gotten more often.
I am watching this almost falling out of my chair, going Rob why are you not selling this thing in the United States just what the hell is going on here. The iT Bra should be well beyond Cisco documentary movies,
Well beyond clinical trials ( especially since it already has FDA approval).
Per my previous research and posting, I can’t believe that mercy virtual Or any of the other medical virtual institutions, are at least field sampling the IT bra.
I would really like to know Rob, where you stand with these institutions.
Now I know for a fact that one of the consulting firms they have hired is working with a California medical virtual institution, but as an investor I only have information that the rest of you have either through research phone calls and Cyrcadia Health news releases.
I believe that very soon I am going to be calling all these institutions on my own, and sending them information on the IT bra...If Cyrcadiahealth wants to sue me so be it !
I’m going to have my wife who is a excellent graphic artist Make up a simple brochure Visual aid regarding the fine points of the IT Bra, let the marketing begin.
Buffet would be proud of us !!!
“If you don’t hold a stock for 10 years, don’t even think about investing in it for 10 minutes”.
Well Mr Buffet, I’ve owned LLBO for 10 years, to think I’ll soon be a “zillionaire”.
What can I say, think positive, on these all or non stocks !
Cisco iT Bra article for newbies:
Innovation
With Early Cancer Detection, IoT Saves More than Money—It Can Save Lives
4100pts
Maciej Kranz - May 24, 2017 - 0 Comments
This week at the Internet of Things World Forum, we’ve been hearing a lot about the transformational value of the Internet of Things (IoT) across many industries – manufacturing, transportation, agriculture, smart cities, retail, and finance. So many new solutions are on display that help organizations either save or make money. But in healthcare, IoT can actually do more than that, it has the potential to save lives.
You may be thinking, “Of course—wearables, remote monitoring, performance tracking. These concepts have been around for a while now.” And yes, these technologies and devices are already working to improve health and fitness. One recent development, however, has really captured my attention because of its potential to help with early detection of breast cancer. That’s the idea behind the connected bra—dubbed the” iTBra” by its inventor, Rob Royea, CEO of Cyrcadia Health. With embedded temperature sensors, this new kind of wearable technology tracks changes in temperature in breast tissue over time. It uses machine learning and predictive analytics to identify and classify abnormal patterns that could indicate early stage breast cancer. And women will be glad to know that they just need to wear the iTBra for 2 to 12 hours once a month as they go about their daily activities—there’s no painful squashing or prodding or radiation involved.
The iTBra fits comfortably under virtually any normal bra and can transmit results to a smartphone.
This technology marks a vast improvement over traditional mammography, which generally doesn’t detect the presence of cancer until it is in Stage 3 or 4. It is also much more accurate than mammography, which produces a high number of both false-positive and false-negative results. Currently, more than 70 percent of biopsies that are done as a result of a suspicious mammogram turn out to be non-cancerous tissue. And in women with dense breast tissue, mammograms miss the presence of cancer more than 50 percent of the time. Because the iTBra relies on different detection technology, its false negative rate has so far been 17.3 percent for all tissue types—an improvement for all women, but especially for those with dense tissue.
Connected bra technology is many times more accurate than mammography in detecting the presence of cancer.
“Detected” is a new short documentary film sponsored by Cisco that shows the development of the iTBra, from the seed of an idea to its acceptance for clinical trials. The power of this documentary is not only about the ground-breaking idea itself, but also about the innovation process. I have been a keen observer and practitioner of innovation and co-innovation for years, and therefore I appreciate how the film realistically depicts the entrepreneurial struggle—a great idea, some false starts, some wrong turns. We also see Rob Royea’s grit and determination as he doggedly persists through obstacles, builds a coalition of the willing across the globe, and spreads his enthusiasm and passion about the project to people around him.
Rob Royea, right, discusses circuitry design with a development partner in Israel.
The connected bra idea is already so powerful by itself; but this is just a start. As Rob Royea says in the film, “What if you can screen three million people in Asia in a single year? What if you can create this mega database through the Internet, that can analyze how some people, versus others, have cancer?“
This is where IoT, in combination with the cloud, machine learning, and analytics capabilities, can truly become transformative. Mammograms—and the radiology expertise needed to interpret their results—are still out of reach for billions of women, especially in poor countries. Now, with inexpensive, non-invasive technology, you can now screen millions of women who have never had access to screening before. And in the process you can gather massive amounts of anonymized data that can help us research and hopefully better understand what factors contribute to a woman getting breast cancer in the first place. In a world where more than half-a-million women die from breast cancer each year, such connected IoT solutions can not only help cancer detection, but also cancer prevention.
The connected bra is just one of the reasons IoT in healthcare is especially exciting to me. Combined with rapid advances in areas ranging from bio- and DNA engineering, to robotics, prosthetics, and remote care, IoT is poised to dramatically improve many aspects of our lives—enhancing not only how long, but also how well we live. This is why I believe it is so important to rally behind entrepreneurs such as Rob Royea. We should support the efforts of current innovators and create incentives and programs for new ventures in the IoT healthcare field. Because in healthcare, the stakes are not just about efficiency or productivity; they’re about our lives.
Tags:
connected braCyrcadia HealthDetectedhealthcareinternet of thingsIoTiTBraMaciej KranzRob Royea
In an effort to keep conversations fresh, Cisco Blogs closes comments after 60 days. Please visit the Cisco Blogs hub page for the latest content.
Hey Squirrel cage, Cytosorbents was an interesting one, I bought @ about 1.50pps sold in 3 range. Everyone was like oh it will never do anything sepsis blood Filtration is very difficult !!!
(Well Where have we heard that before.) Cytosorbents 1st got CE mark
Overseas, well imagine that, trading in the mid $8.00 range now.
Look at the biggest problem in hospitals, Sepis blood poisoning, people don’t die from surgeries they die from
Infections.
iT Bra is really a great product at 80% pos trial Breast Tumor Identification. Given that an extremely high amount
Of Asian women have dense breast tissue (Can’t remember exactly why but you can find it if you do some
research), it’s only natural and very smart marketing to introduce the pruduct in Asia.
It’s interesting I’ve held the stock since 2009...LLBO 1,933,000 shares, in my till death do us part portfolio!
Time shall tell ??????
Cisco very happy with 82% effective diognoses rate for iT Bra vs
42% using traditional breast cancer tech on dense breast tissue.
Look for some noise from Cisco later this year, when the product
distribution begins in Asha, land of the dense breast tissue market.
(Preliminary breast tumor “blood”test Only 33% effective, and a very
long way until market rollout 5-6-7 yrs???)
https://www.itspmagazine.com/from-the-newsroom/detected-a-movie-iot-wearable-tech-breast-cancer-and-cisco
Jan 22, 2018
“IT appears the gamble has paid off for Cisco & Rob Royea.”
PPS Target .03-.05 fall/winter 2018
Virtual Medical Care Huge Future: Glad to see that Cyrcadia will be indirectly involved with Kaiser Permanent
(I brought this up as a target mkt below, prior to their 2017-2018 report release, glad to see they are going right
after the Virtual med mkt.)
Let’s just look at what is literally appearing before our eyes To help answer this question
“This is the future of Medicine...”
Telemedicine Revolution (patients/doctors converse anywhere)—Fact, Hospital Without Patients (virtual care) 2016 mega growth industry sales of $14 Billion Dollars, growth projection
expected of $36 Billion Dollars by 2020, (2 yrs)WOW, project that growth line and
You fall out of your seat (iT Bra I would say is properly named).
Mercy Virtual medical bldg is 6 miles from my home, a mega structure loaded with over
400 doctors, nurse specialist,and med technicians (not one hospital bed). All who supported more than 44 hospitals in the Mercy network,
in over 10 Midwest states (had over 750,000 thousand patients just last year.)
(Why? Patient convenience, privacy, more efficient healthcare, saving money & more important life’s).
1)Mercy Virtual 2)Kaiser Permanente 3)Cleveland Clinic 4)Intermountain Health Care, 5)Dignity Health,
6) Avera Health—just names of mega hospital Major healthcare providers networks with millions of patients getting in on the game...
AND One hell of a big game it’s going to be.
One strategy these players are aiming is Primary Preventaive Medicine “Primary Care”, ahhh musical notes
to who else, but our cheer leaders the Insurance Companies, a growing garden of health care medical care
payout savings, and wow are they cheering...!
Go iT Bra Go Go Go...
So $1/PPS !
So who do you think Cyrcadia Health is targeting ask your self ?—why the extensive clinical trials when they already have FDA Clearance, and mktg/sales program in Asia, because they want to get it right (their AI Artificial intelligence algorithm)
This iT Bra no pun intended fits right into the “Telemedicine Revolution” and the timing could not be better.
(reducing anxiety, commute time/expense/carbon foot print, giving privacy and saving a life for millions of women connected all over the world, ask yourself what would you pay to save your life—a mere $30-40-50
Dollars for such a product, what would an insurance co pay to save millions of dollars ?
Yes the TeleMedicine evolution is here fellow investors (I am currently holding 2 Mil shares LLBO)
My hats off to Cyrcadia and Mercy Virtual for preventing/ reducing early unnecessary deaths,
hospital admissions, emergency dept visits, saving untold millions of dollars.
The price of admission is life...
I guess only time and a life saved will answer thePPS question.
((But in the mean time12-18 months PPS target of .12-18 PPS with a viable product, the exponential growth
market opportunity is just to explosive to ignore))
Previous post # 24768, which u can enter the post num at the top GoTo search box, has investigative info
on some current investors as well as clinical trial data.
Good day to all.
AARP magazine article Feb/March 2018
—“The Digital Doctor Is In” , explores how telemedicine is transforming healthcare.
Excellent article and anyone that invest in any kind of healthcare should definitely read.
(I know one thing the executives at Cyrcadiahealth.com are cer
Cal trial is Closed...Oh is still open...
Due some research...
Opportunity, just need the dam product
Let’s just look at what is literally appearing before our eyes To help answer this question
“This is the future of Medicine...”
Telemedicine Revolution (patients/doctors converse anywhere)—Fact, Hospital Without Patients (virtual care) 2016 mega growth industry sales of $14 Billion Dollars, growth projection
expected of $36 Billion Dollars by 2020, (2 yrs)WOW, project that growth line and
You fall out of your seat (iT Bra I would say is properly named).
$1/PPS !
Mercy Virtual medical bldg is 6 miles from my home, a mega structure loaded with over
400 doctors, nurse specialist,and med technicians (not one hospital bed). All who supported more than 44 hospitals in the Mercy network,
in over 10 Midwest states (had over 750,000 thousand patients just last year.)
(Why? Patient convenience, privacy, more efficient healthcare, saving money & more important life’s).
1)Mercy Virtual 2)Kaiser Permanente 3)Cleveland Clinic 4)Intermountain Health Care, 5)Dignity Health,
6) Avera Health—just names of mega hospital Major healthcare providers networks with millions of patients getting in on the game...
AND One hell of a big game it’s going to be.
One strategy these players are aiming is Primary Preventaive Medicine “Primary Care”, ahhh musical notes
to who else, but our cheer leaders the Insurance Companies, a growing garden of health care medical care
payout savings, and wow are they cheering...!
Go iT Bra Go Go Go...
So $1/PPS !
So who do you think Cyrcadia Health is targeting ask your self ?—why the extensive clinical trials when they already have FDA Clearance, and mktg/sales program in Asia, because they want to get it right (their AI Artificial intelligence algorithm)
This iT Bra no pun intended fits right into the “Telemedicine Revolution” and the timing could not be better.
(reducing anxiety, commute time/expense/carbon foot print, giving privacy and saving a life for millions of women connected all over the world, ask yourself what would you pay to save your life—a mere $30-40-50
Dollars for such a product, what would an insurance co pay to save millions of dollars
iT Bra $1/PPS !
Yes the TeleMedicine evolution is here fellow investors (I am currently holding 2 Mil shares LLBO)
My hats off to Cyrcadia and Mercy Virtual for preventing/ reducing early unnecessary deaths,
hospital admissions, emergency dept visits, saving untold millions of dollars.
The price of admission is life...
So I ask you $1/PPS, I guess only time and a life saved will answer that question.
((But in the mean time12-18 months PPS target of .12-18 PPS with a viable product, the exponential growth
market opportunity is just to explosive to ignore))
Previous post # 24768, which u can enter the post num at the top GoTo search box, has investigative info
on some current investors as well as clinical trial data.
Good day fellow humans
AARP magazine article Feb/March 2018
—“The Digital Doctor Is In” , explores how telemedicine is transforming healthcare.
Excellent article and anyone that invest in any kind of healthcare should definitely read.
(I know one thing the executives at Cyrcadiahealth.com are certainly readin
post asked $1.00 / PPS ??? “LLBO” Explosive Opportunity
Let’s just look at what is literally appearing before our eyes To help answer this question
“This is the future of Medicine...”
Telemedicine Revolution (patients/doctors converse anywhere)—Fact, Hospital Without Patients (virtual care) 2016 mega growth industry sales of $14 Billion Dollars, growth projection
expected of $36 Billion Dollars by 2020, (2 yrs)WOW, project that growth line and
You fall out of your seat (iT Bra I would say is properly named).
$1/PPS !
Mercy Virtual medical bldg is 6 miles from my home, a mega structure loaded with over
400 doctors, nurse specialist,and med technicians (not one hospital bed). All who supported more than 44 hospitals in the Mercy network,
in over 10 Midwest states (had over 750,000 thousand patients just last year.)
(Why? Patient convenience, privacy, more efficient healthcare, saving money & more important life’s).
1)Mercy Virtual 2)Kaiser Permanente 3)Cleveland Clinic 4)Intermountain Health Care, 5)Dignity Health,
6) Avera Health—just names of mega hospital Major healthcare providers networks with millions of patients getting in on the game...
AND One hell of a big game it’s going to be.
One strategy these players are aiming is Primary Preventaive Medicine “Primary Care”, ahhh musical notes
to who else, but our cheer leaders the Insurance Companies, a growing garden of health care medical care
payout savings, and wow are they cheering...!
Go iT Bra Go Go Go...
So $1/PPS !
So who do you think Cyrcadia Health is targeting ask your self ?—why the extensive clinical trials when they already have FDA Clearance, and mktg/sales program in Asia, because they want to get it right (their AI Artificial intelligence algorithm)
This iT Bra no pun intended fits right into the “Telemedicine Revolution” and the timing could not be better.
(reducing anxiety, commute time/expense/carbon foot print, giving privacy and saving a life for millions of women connected all over the world, ask yourself what would you pay to save your life—a mere $30-40-50
Dollars for such a product, what would an insurance co pay to save millions of dollars
iT Bra $1/PPS !
Yes the TeleMedicine evolution is here fellow investors (I am currently holding 2 Mil shares LLBO)
My hats off to Cyrcadia and Mercy Virtual for preventing/ reducing early unnecessary deaths,
hospital admissions, emergency dept visits, saving untold millions of dollars.
The price of admission is life...
So I ask you $1/PPS, I guess only time and a life saved will answer that question.
((But in the mean time12-18 months PPS target of .12-18 PPS with a viable product, the exponential growth
market opportunity is just to explosive to ignore))
Previous post # 24768, which u can enter the post num at the top GoTo search box, has investigative info
on some current investors as well as clinical trial data.
Good day fellow humans
AARP magazine article Feb/March 2018
—“The Digital Doctor Is In” , explores how telemedicine is transforming healthcare.
Excellent article and anyone that invest in any kind of healthcare should definitely read.
(I know one thing the executives at Cyrcadiahealth.com are certainly reading it)
A product in need, is a product indeed ??
Post 24768 clinical trial / investor info. Dec 2017
California clinical trial has been done for sometime,Ohio is 2/3 or more.
My wife could enroll OH Trial, but we live in MO.
So we’ll see what 2018 brings...
Good post...
PPS 7.5€ still holding...
Eva Bra ( according to May26,2017–Article called breast cancer detection bra designed by teen almost lost his mom) To be released within two years that would be around 2019.
Has anyone seen any articles about Cyrcadiahealth.com responding to this???
Certainly sounds like Patent infringement !
I emailed the company today asking if they were responding to this to investors.
Be interesting to know where the Eva Bra stands what kind of backing,how much testing, are they running their own clinical trials in Mexico ? Etc.
This is a concern especially if it’s an easy to use accurate and an inexpensive device that can be offered in Third World countries. ( this is the market that the IT Bra is going after to start the ball rolling.
Comments anyone...?
Tic toc, 2018 will in all probability be a big year for this
Modern tec co., as level of interest grows & clinical trial complete
FDA fast track approval is a foregon conclusion.
(Sale of the company will conclude—.05/.10 pps)
Tic tic, still holding 1.9 Mil shares...This is the time to not be caught trading
Because it will be fast and furious.
1) trial completion announcement
2) FDA submittal. “. “
3)FDA fast track approval (Remember first device submittal approved.)
4) Sale of Company Per original VC and Angel requirements.
??????
Good post, you obviously did your deep research, takes time.
Most posters do little to none. Then they question us, The information is out there.
My previous post took almost 3 hours, just to research who the big investors are.
And if they still hold the investment ( which as I mentioned they do).
Clinical trial: Well let's look at what we do know versus total speculation.
The majority if not all of the original investors are still invested.
RB investments, Reno angel group, and The Propell group are still invested.
Most interesting is that the propell group likes to invest in companies that could be disruptive technology.
The angel group has a target of $100 million potential market to qualify for their capital outlay.
El Camino has closed the IT bra enrollment, and OSCCC is still open for enrollment.
Indications are that the IT Bra has shown 82% or better efficacy.
All The above I do know
So have they or have they not filed for FDA approval, they had mentioned in the past
That FDA submittal would occur simultaneously ?
How soon will they make any kind of press release ?
Will they sell the company or look for further large VC investor ?
These things I don't know
One last thing I forgot to mention is that one of several criteria other than $100 Mill mkt opportunity was that the Reno angel groups investment with any company had to have a clear exit strategy, which was that
The start up company had to be sold or significant investment by a VC, in other words they wanted their share of the pie immediately.
All of the information above took several hours of investigating online.
More like J&J or some other consumer health
Product Co., with a mass mktg base to health
Professionals.
With El Camino Hospital trial not enrolling anymore, Cyrcadia last public statement of 83% or better efficacy,
and Ohio State CCC still enrolling people for the study (The fact that the Ohio State trial is still open is great and could possibly mean they are seeing good results), I'd say FDA approval is getting closer and closer, maybe less than a year out. 2 million shares held her for nine years what's one more.
As I said in my previous post go to the El Camino Hospital site & pull up "cancer" clinical trials
You will find the trial listed and it's status is "not recruiting".
Trial complete at El Camino hospital
(Per El Camino site--clinical trial listing.)
Ohio State trial still going, per Leigh Nelson RN etc etc
At OSCCC.
Cyrcadia list 173 trial sample, does anyone know if they ever talked
about how many subjects per site would be used ?
(I know OH has a huge breast cancer department)
iT Bra has not finished the clinical trials.
I have been surprised to see some posters think that they have already applied for FDA 510k approval.
They may have started the paperwork but quite obviously cannot submit until trial data is available.
Then you have the FDA approval waiting time, and only God would know how long that would take.
Now I'm not sure if they can get fast track for something like this or not ? The trial data would have to be pretty convincing.
As far as domains PPS Analysis goes, I could easily see some of those numbers given the right marketing/didtrbution network, let's just say someone like Johnson & Johnson ?????
PPS .05 cents is about where I came up with my valuation several years ago.
(For new investors google LLBO stock forum and click on 1st hit, for Co info and valuation)
Very easy to value given the size and the demand for a product like this.
Just needs to complete successful trial,approval,and Mktg...!
(over 2 million women worldwide will be diagnosed with breast cancer this year throughout the world.
Susan G Kolmon statistics not mine)
39 million women get mammograms per year at 8743 Health facilities (USA only stat)
Does not include the rest of the world. Approximately 10% of these will need follow-up mammogram &
High risk candidates will need the mammograms plus recommended MRI scan annually.
Cost aproximately $300-$500 per year, not including doctors fees.
Valuation is fair.
Given the fact that screening detection in 3rd world countries
Supposedly cost more than treatment, a low-cost screening method would be welcomed.
(most Third World cases are detected in stage two and three)
Unlike the USA,Europe and other developed countries breast cancer more commonly is detected in stage one.
Given the scope of this market both third world & developed, any good clinical trial data-
Will not only be a blessing for early detection (lives saved), but Will also create a rapid rise
In new shareholders.
Currently LLBO has about 2.9 billion shares being held by less than "1200" people. If and when we start to see a rise in the number of shareholders (compounding shareholder growth 2x 3x 4x etc.), the recognized value will be initiated. Then and only then will we will see compounding volume move PPS considerably.
(trading range of .01 / .03 quite easily)
Many years ago I did a full revenue analysis and projected PPS.
It really was quite staggering and pretty well matched up with all the independent studies for projected PPS.
Let's keep our fingers crossed.
Sell out at .05 no less (2 mil shares for 4 yrs now)
.05 as previously stated fair value with UE & FDA submittal
Per post# 3637 dated 1-17-15 study by Life Science Strategy Group
LLBO valuation pre market.
(Simply update to 2016 est valuation of 391 Mill. and divide by
2012 est of 56 Mill. = 6.98 [6.98 x .0077= .054 per share value]
Life anything these are all guesses based on current statistics and estimated margins...
valuation ce & 510k approval
@ current OS level ~.05/share
any comments ?
PPS Est. $4.16 EU--$12.60 US/EU,The several hundred million dollar plus product
agree, very revealing letter, interesting part about the date to be released almost like there is more than just the study results coming,,any comments anyone ???
Cytosorbents Co.(risk) ctso--EU recently approved for sepsis treatment and results due June/July 2011 (already showing a 49.1% IL-6 cytokine reduction along with std of care treatment)
If...approved as broad secondary treatment eu and us this company will definately shine (the holy grail).
http://messages.finance.yahoo.com/Stocks_%28A_to_Z%29/Stocks_C/threadview?m=te&bn=55421&tid=35130&mid=35130&tof=6&frt=2#35130
patent filed, fin. out, now fda update for allay/actipatch (benchtest completed) moving along...
study restrictions...
PPS Est. $4.16 EU--$12.60 US/EU,The several hundred million
after further dd, recent developments & concerns about dilution i've gone back & dug deeper for my new PPS target...
PR article:Research & Diagnostic Antibodies LLC--http://markets.about.com/popular.htm/?GU... per the article---
"" it is well accepted that better clinical outcomes are achieved when treatment is begun "immediately after diagnosis". The cost of treating septic patients in an ICU can add ""$10,000"" or more per day to a patient’s bill with treatments lasting at least two days and often more than 20 days. Since one in eight ICU patients are at risk for sepsis, the cost in the United States alone to treat sepsis exceeds $30 billion a year.""
{my take on this article--ctso has the possibility of selling cytosorb in lg quantities}
Now read this article, ""it will raise the hair on your back""--
surviving sepsis.com/background
Over 18 million cases of sepsis occur each year – that’s equivalent to the entire population of Denmark, Finland, Ireland and Norway added together each year (2). Worryingly, the number of severe sepsis cases is set to grow at a rate of 1.5% per annum from the current annual incidence of 3.0 cases per 1,000 of the population (2). This amounts to an additional 1 million cases per year in the USA alone by 2020.
One doctor has an interesting statement to make about the primary STD OF CARE recommended:
“For example, there is not strong evidence that says that giving antibiotics is a top-notch practice of medicine and that it saves lives compared to not giving antibiotics,” points out co-author Sean Townsend, MD, associate director of the medical ICU at Rhode Island Hospital in Providence. “But nobody on the committee would ever feel comfortable saying that.”
{OK, so the "primary treatment" issued by the Surviving Sepsis Campaign Guidelines is in ...QUESTION? WOW...}
{now maybe you will understand the full potential of ctso filters as an adjunct therapy
$$$, New world guidelines from the Surviving Sepsis Campaign Org. should read: Institute interventions rapidly with hemoperfusion as an adjunctive therapy (cytosorb filters)}
Worldwide annual sepsis expense runs in multi billions( that number does not include additional hospital expense for lawsuits,& extended incident stays-many of the EU nations actually reward hospitals for getting patients out faster "translated"-give us a product that can get the patient the hell out faster by one day & we make money.
New pps calculation: EU & US estimated sepsis deaths (~225,000 US & ~135,000 EU = 360,000 deaths/yr or multiply by 3 as 1/3 or more die that get severe sepsis = 1,080,000 annually severe sepsis incidents "conservative"..........
Dr.Chan stated "cytosorb has an high margin & will sell for about ~$500/per filter" (one incident is 7 days on avg,1 filter/day, so one patient incident cost $3500)
Let's just use a conservative "10% of annual severe sepsis incidents" to get our pps calculated:
1.088 mil.annual incidents x 10% = 108,000 incidents x $3500 = $378 Mil sls x ~.50 margin = $189 million profit....................
(Dr. Chan said the margin was to exceed 40-60 percent)
Using current O/S of ~140 Mil shares
& estimated diluted shares of 300Mil conservtive pe of 20, we get an EU/US PPS of:
o/s pps = $27 US/EU
diluted pps = $12.60 US/EU.
(the EU alone would be 1/3 of the above pps that is 1/3 the incidents per above, so $9 and $4.16 respectively)
Now they claim partnering may be needed,so assuming we split the margin ??? reduce the top by 1/2 or less? Either way you have a clear winner here (good 28 day mortality numbers will set this Co. on fire). Remember this is for only severe sepsis & none of the other markets Dr. Chan is targeting.
GLTA & REMEMBER DUE YOUR DD "on your own".
1% of $10 BILLION DOLLARS--pps .32 12-May-11 10:18 am
10% of $1 Bill = a great buy for a major player...
The tech does work (pemf)NO DOUBT AT ALL, do some dd & read the articles...upon approval,distribution agreements will most likely be implemented-biel will gain shelf space in major retail outlets (biel has already talked to nat.dist. of feminine hygiene products, link listed below -Andrews's (ceo) commented "In the States, however, we have had conversations with manufacturers and distributors of feminine hygiene products, who have experienced significant interest in a Allay menstrual pain relief products, but they're all preliminary discussions. They say, "Great, let us know what happens with the FDA, because we're all interested."
http://biomedreports.com/articles/most-p...
OK great, that's just one fda pending product, but the big one submitted is for Musculosekletal Disorders (mainly back pain )when approved it does not take much thinking to figure out who would be interested lg.nat.dist./ pharma. --- we don't have many people in the US with back pain do we ??? or i guess we don't really have any surgical procedures in the US do we ??? (hell i forgot about the rest of the world) The world therapeutic market is est. at over $10 Billion...(sorry i lost the link)
The indi.analyst est. pot. sales at $1 Bil.(that is the applicable portion of the world wide mkt of $10 Bill) worldwide for biel products (per last yr's CC), using just a conservative 10% gives us sales of $100 Mil((1% of $10 Bill.)) @ a conservative 30% margin (biel margins avg > 60%) = $30 Mil profit,,30 Mil divided by 1.5 ~billion shares o/s = .02 cents/per share X 16 PE = $.32 PPS
$.32 PPS--------(indi.analyst est. ~.30-.50 near term OK, ONE YR AGO!),
{{note: in consideration of another poster my .32 WAS diluted by margin split with national distributors, how much i don't know, but a buyout per their ceo would be most likely}}
As some of u have posted, professional sports teams, college sports, pet mkt., sr. healthcare facilities will all be great mkt. pot. for biel.
All biel production is in China now & they have brought on a heavy hitter as chairman (has exp with fda). This Co. is real, pemf tech is real & not going away.
As biel already has an "fda approved product" ((this is why they filed 510k's & not a PMA with the fda)), the new products will be approved one way or another eventually. The audit has been completed. Pinks has been updated. Bench test submittal to fda any day now for Allay/Acti-Patch. Audit sign off and posting also coming.Position: Long well over one million shares
Sentiment : Strong Buy
Allay & Acti-patch bench test submittal to FDA soon. 12-May-11 09:52 am
Allay/ActiPatch
Hi Mike,
Thank you for contacting us. The bench test is completed but we paused the submission because we wanted to file a provisional patent and we will send to the FDA within the next few days. The bench test was for further explanation of clinical evidence of the technology of our products.
We are still waiting on the audit firm to sign off on the financials. We hope to post the Q4 2010 and Q1 2011 financials within the next couple of days.
Please let us know if you have any further questions.
Thanks!
tic toc...
PPS Est. $4.16 EU--$12.60 US/EU,The several hundred million dollar plus product...calculation link below:
http://messages.finance.yahoo.com/Stocks_%28A_to_Z%29/Stocks_C/threadview?m=tm&bn=55421&tid=35130&mid=35130&tof=3&frt=2
try 2.66 (Eli Lil. share of mkt)
THINK THIS IS WHY CHAN IS SO POSITIVE,EARLY MARCH 2011 Biotuesdays interview article exerts ???$$$ (keep in mind he already had filed for EU-approved 3 wks later & knew the results of over 90 incidents & 650 treatments)
"We believe that CytoSorb has the potential to fundamentally change the treatment paradigm of critical care medicine,” Dr. Chan says
Dr. Chan says CytoSorb has “blockbuster potential as a cytokine filter,” with a U.S. and EU total addressable market of $10 billion-to-$15 billion in critical care applications. “There is limited competition, we have a differentiated best-of-breed approach, CytoSorb is plug-and-play compatible with existing dialysis machines throughout the world and has a highly profitable razor/razorblade business model, we are hopefully near-term to commercialization, and are addressing major unmet medical needs.”
Eli Lilly’s Xigris is the only drug approved for sepsis, but is not widely adopted because of its $8,000 cost, as well as safety and efficacy issues. The drug has an annual sales run of about $200 million, well below Lilly’s original forecast of at least $1 billion a year.
Dr. Chan points out that some patients with autoimmune diseases such as rheumatoid arthritis, psoriasis or Crohn’s disease are given anti-cytokine therapies such as Enbrel, Remicade or Humira, which together have sales of some $14 billion a year worldwide.
“This is cutting-edge technology that has multiple potential applications for both civilian and military use,” Dr. Chan says. “Infection and sepsis, polytrauma, and severe burn injuries are leading causes of poor outcome not just in the general population but also for our nation’s war fighters. We are excited about the prospects of making this technology widely available to physicians and patients in need.”
http://biotuesdays.com/2011/03/22/2011-could-be-transition-year-for-cytosorbents/
(i now most of u have seen this so mainly for new people, none the less very interesting when u read the exerts from the article in that order...$)
Interview exerts:
“We believe that CytoSorb has the potential to fundamentally change the treatment paradigm of critical care medicine,”
Dr. Chan says CytoSorb has “blockbuster potential as a cytokine filter,” with a U.S. and EU total addressable market of $10 billion-to-$15 billion in critical care applications. “There is limited competition, we have a differentiated best-of-breed approach, CytoSorb is plug-and-play compatible with existing dialysis machines throughout the world and has a highly profitable razor/razorblade business model, we are hopefully near-term to commercialization, and are addressing major unmet medical needs.”
http://biotuesdays.com/2011/03/22/2011-c...